Leukapheresis Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Leukapheresis Market Trends and Insights

Rising Incidence of Leukemia and Associated Hyperleukocytosis

Incidence curves for acute myeloid leukemia continue to climb, with global cases moving from 79,372 in 1990 to 144,645 in 2021 and trending toward 184,287 by 2040.^{[1]Peter Lee et al., “Global Burden of Leukemia,” BioMedical Engineering Online, biomedcentral.com} Hyperleukocytosis, defined as white-blood-cell counts above 100,000/µl, demands urgent cytoreduction to prevent respiratory distress and neurologic complications.^{[2]R. H. Liu, “Management of Hyperleukocytosis,” ScienceDirect, sciencedirect.com} Leukapheresis has therefore transitioned from elective therapy to standard emergency intervention. Male patients register steeper growth in incidence than females, while adults aged 80-84 exhibit the highest case density. Health-system protocols now automatically route eligible leukemia admissions to apheresis units, ensuring same-day access and cementing procedure volumes across tertiary centers in the leukapheresis market.

Growing Need for High-Yield, Research-Grade Leukopaks

CAR-T and natural-killer-cell manufacturers increasingly specify leukopaks that deliver 10 billion or more mononuclear cells per collection.^{[3]Biomol GmbH, “Leukopak Product Specification,” biomol.com} Manufacturing failure rates correlate directly with starting-material quality; a compromised leukopak can invalidate a USD 300,000 manufacturing run.^{[4]Lisa Rein, “Cell Therapy Manufacturing Failures,” Cell & Gene, cellandgene.com} Over 500 active clinical trials now depend on donor-derived immune cells, and the pivot toward allogeneic “off-the-shelf” therapies elevates recurring demand. Automated continuous-flow centrifugation secures tight leukocyte concentration windows and reduces red-cell contamination, streamlining downstream enrichment. Standardized donor-screening algorithms supported by AI scheduling software raise per-center capacity, enabling suppliers to meet escalating leukopaks requisitions without overtaxing staff.

Rapid Expansion of CAR-T and Other Cell & Gene-Therapy Manufacturing Facilities

Bristol Myers Squibb commissioned a 244,000 sq ft CAR-T plant in Massachusetts in 2025 to lift Breyanzi output. Every production slot begins with leukapheresis; capacity additions therefore deliver a direct linear pull on disposables and device placements. Median vein-to-vein times still span 3-5 weeks, creating a global race to shorten supply chains. Decentralized models, such as Excellos’ partnership with Galapagos, target 7-day cycles by colocating leukapheresis suites with modular vector lines. Equipment vendors now bundle regulatory-grade training and remote-monitoring services to help nascent sites pass validation faster, further broadening the leukapheresis market.

Widespread Uptake of Continuous-Flow Apheresis Systems

Systems like Spectra Optia offer automated interface management that tunes plasma-to-anticoagulant ratios in real time, cutting citrate toxicity events by 40% in published audits. Continuous-flow technology trims processing volumes, lowering procedure time and freeing staff to supervise additional chairs in high-throughput centers. When a large Midwest clinic moved to extended-hour shifts, it reduced peripheral-blood stem-cell collection sessions per patient from 3.2 to 1.7 within six months. Cloud-linked devices feed session data into AI scheduling tools, improving donor return rates and smoothing inventory across centers. The efficiency dividend justifies capital upgrades even for mid-volume sites, stimulating device growth within the leukapheresis market.

High Costs Associated with Therapeutic Leukapheresis Procedures

Patient invoices for single-dose CAR-T therapies routinely exceed USD 500,000 and reach USD 1 million in complex pediatric cases, with leukapheresis comprising a meaningful early share. Stand-alone private collection centers operate 32% cheaper than hospital-based settings, yet most low- and middle-income regions lack such facilities. Equipment depreciation, single-use kits, and mandatory sterility audits inflate baseline costs. Although Medicare’s 2025 rule broadened reimbursement definitions, coverage gaps linger in many public systems aabb.org. Until payors harmonize around bundled-payment models, high procedural outlay will temper demand in price-sensitive geographies.

Shortage of Skilled Apheresis Professionals

The National Marrow Donor Program warns that physician retirements will outpace new hematopoietic-cell-transplant specialists by 2027. Certified apheresis nurses also remain in short supply, and burnout risk rose during pandemic redeployments. While automated devices reduce manual tuning, real-time clinical decisions still require experienced oversight, especially when calcium shifts or hemodynamic instability arise. Certification boards respond by rolling out accelerated fellowships, yet the training pipeline trails the leukapheresis market’s demand curve. Vendors now fund remote-learning modules that cover equipment operation and quality-control protocols, but the talent gap persists as a structural headwind. 

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Devices Reshape Collection Efficiency

Leukapheresis devices are expanding at a 10.37% CAGR from 2026-2031 as centers upgrade to continuous-flow platforms with optical-detection sensors. The leukapheresis market size for devices equaled USD 113.34 million in 2025 and is positioned to outpace disposables growth through the forecast. Spectra Optia’s algorithmic interface and the FDA-cleared Rika Plasma Donation System V2.1 exemplify device-level innovation. Product pipelines now include portable bedside units that target point-of-care leukoreduction in hematology wards and emergency departments. 

Disposables retained 50.68% of leukapheresis market share in 2025 due to their single-use safety profile and recurring-revenue model. Elevated procedure volumes ensure consistent kit sales, reinforcing manufacturer cash flows and incentivizing investment in integrated tubing sets that cut priming times. Leukoreduction filters remain a mature niche, yet demand persists because many blood-bank protocols still enforce universal leukocyte reduction. Columns and cell separators support specialized pathogen-reduction workflows, though their penetration concentrates in academic centers. Overall, packaging disposables with capital-equipment leases locks in account loyalty, anchoring the segment’s leadership within the leukapheresis market.

By Application: Research Use Accelerates Innovation

Therapeutic indications commanded 63.05% of revenue in 2025 aided by guideline status for hyperleukocytosis and stem-cell mobilization. This dominance prevails even as the research segment logs a brisk 11.42% CAGR through 2031. More than 1,100 cell- and gene-therapy developers now require standardized leukopaks for vector optimization, potency assays, and release testing. 

Diagnostic leukapheresis further widens the use case by boosting circulating-tumor-cell detection 30-fold over peripheral draws. FDA approvals for novel autologous products, such as afamitresgene autoleucel and obecabtagene autoleucel, validate procedure reliability in advanced oncology protocols. The dual track of established treatments and investigative pipelines keeps utilization high across hospital and industry settings, positioning research as a durable growth pillar for the leukapheresis market.

By End User: Manufacturers Capture Highest Growth

Hospitals and transplant centers accounted for 46.10% of 2025 revenue because they house patient-ready apheresis suites and manage first-line hyperleukocytosis care. Yet cell- and gene-therapy manufacturers show the sharpest trajectory at 12.01% CAGR through 2031. The leukapheresis market share controlled by commercial plants rose from 18% in 2022 to 23% in 2024 as firms internalized collection capacity to de-risk supply. 

Blood centers and donor clinics retain a vital role as they recruit healthy donors for allogeneic trials, while academic institutions pilot advanced protocols and validate next-generation columns. Hybrid models now emerge: regional blood centers embed GMP suites to serve biotech clients, blending donor-acquisition strength with manufacturing infrastructure. University Hospitals in the United States processed 4,300 more leukopak samples in 2024 than 2023, signaling converging clinical and manufacturing priorities. This ecosystem evolution enhances overall procedure density and sustains broad-based growth for the leukapheresis market.

Geography Analysis

North America led the leukapheresis market with a 45.20% share in 2025. U.S. leadership stems from FDA regulatory clarity and unmatched CAR-T approval volume, including the 2024 clearances of afamitresgene autoleucel and obecabtagene autoleucel. Medicare’s 2025 reimbursement expansion for therapeutic apheresis further bolsters financial viability. Canada and Mexico contribute through cross-border clinical-trial networks and joint manufacturing initiatives that streamline donor logistics. Concentration of device makers such as Terumo BCT and Haemonetics within the region speeds tech adoption cycles, sustaining North America’s prime position in the leukapheresis market.

Europe remains a mature yet dynamic arena. EMA guidelines deliver consistent evaluation pathways for CAR-T products, fostering steady demand for high-performance leukapheresis systems. The European Blood Alliance campaigns for two million additional voluntary donors, incentivizing centers to adopt continuous-flow platforms that maximize platelet yield and donor comfort. Germany, France, and the United Kingdom invest in integrated apheresis suites tied to national cancer plans, while Italy and Spain expand regional cell-therapy nodes. Supply-chain resilience, particularly in cold-chain trucking, dominates investment agendas and stabilizes procedure throughput.

Asia Pacific posts the fastest growth at an 11.02% CAGR to 2031. Japan’s advanced geriatric care drives premium device uptake, whereas India benefits from government-backed cell-therapy clusters in Hyderabad and Bengaluru. Regulatory authorities in Australia and South Korea introduce accelerated review pathways mirroring FDA’s RMAT designation, catalyzing early commercial rollouts. Overall, infrastructure modernization, coupled with local manufacturing incentives, transitions Asia from technology import destination to fully integrated supply-chain hub in the leukapheresis market.

Regulatory Landscape

In the United States, leukapheresis and apheresis blood-cell separator systems are commonly regulated as FDA Class II devices and typically enter the market via the 510(k) premarket notification pathway. Sponsors generally demonstrate substantial equivalence to a predicate (often aligned with FDA product codes for blood and blood-product manufacturing equipment). After initial clearance, manufacturers must maintain establishment registration and device listing, and comply with post-market safety reporting and quality system requirements that affect software updates, disposables compatibility, and servicing documentation across installed bases.

In Europe, leukapheresis-related device conformity under the EU Medical Device Regulation (EU 2017/745) can intersect with advanced therapy medicinal product (ATMP) frameworks when ancillary substances or human blood derivatives are involved. This brings Notified Body review and, in certain cases, European Medicines Agency consultation on the quality and safety of the ancillary substance. Internationally, meeting relevant ISO standards used for extracorporeal blood purification and apheresis container systems (for example, ISO 8637-3 and ISO 3826-4) supports technical documentation, interoperability, and cross-border deployment for centers supplying research-grade leukopaks into GMP workflows.

Market Opportunities and Future Outlook

Capacity creation and new care-delivery models are creating whitespace in leukapheresis access for cell and gene therapy programs, particularly where hospital chair time and trained staff are limiting factors. In April 2026, Northwest Biotherapeutics established a dedicated leukapheresis clinic at The London Welbeck Hospital, a response to UK collection-capacity constraints that also points to a broader opportunity for dedicated, procedure-focused sites serving both therapeutic demand and research-grade leukopak supply. Mobile and decentralized collection is also progressing into implementation, with BBG Advanced Therapies launching a mobile leukapheresis center in collaboration with Kite in July 2026 to extend patient reach for CAR-T pathways.

Upstream manufacturing investments and downstream automation are reinforcing demand for standardized, traceable starting material and closed processing around leukapheresis collections. Johnson and Johnson announced a more than USD 1 billion investment in a next-generation cell therapy manufacturing facility in Pennsylvania in 2026, which underscores how large-scale CGT buildouts translate into recurring needs for collection scheduling, chain-of-identity controls, and validated transport and cryopreservation interfaces. On the process side, industry emphasis on automated, closed workflows, including wider adoption of fully automated immunoselection platforms and integrated cryopreservation services, aligns with the market shift toward higher-yield leukopaks and reduced handling variability, with faster vein-to-vein cycles. This creates practical demand for device suppliers, disposable-kit providers, and specialized logistics partners that can deliver GMP-ready, auditable leukapheresis ecosystems.